| Long-Term Effects of COVID-19 | Lifetime | 21 | GB 5 | 99.51 |
| COVID-19 Clinical Research Studies | Lifetime | 56 | GB 4 | 99.61 |
| Bacterial Infections and Vaccines | Lifetime | 21 | GB 5 | 99.63 |
| COVID-19 and Mental Health | Lifetime | 37 | GB 9 | 99.38 |
| COVID-19 and healthcare impacts | Lifetime | 33 | GB 8 | 99.04 |
| Pneumonia and Respiratory Infections | Lifetime | 43 | GB 4 | 99.73 |
| COVID-19 Impact on Reproduction | Lifetime | 19 | GB 4 | 99.17 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 146 | GB 11 | 99.31 |
| Respiratory viral infections research | Lifetime | 97 | GB 11 | 99.50 |
| SARS-CoV-2 detection and testing | Lifetime | 47 | GB 5 | 98.68 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 118 | GB 10 | 99.13 |
| Influenza Virus Research Studies | Lifetime | 356 | GB 36 | 98.32 |
| Virology and Viral Diseases | Lifetime | 216 | GB 27 | 97.95 |
| Kawasaki Disease and Coronary Complications | Lifetime | 152 | GB 9 | 96.68 |
| Streptococcal Infections and Treatments | Lifetime | 526 | GB 33 | 97.24 |
| Neonatal and Maternal Infections | Lifetime | 238 | GB 14 | 96.25 |
| COVID-19 epidemiological studies | Lifetime | 763 | GB 100 | 95.53 |
| Travel-related health issues | Lifetime | 529 | GB 59 | 85.83 |
| Poxvirus research and outbreaks | Lifetime | 979 | GB 91 | 85.58 |
| Long-Term Effects of COVID-19 | 2021-2025 | 8 | GB 3 | 99.82 |
| COVID-19 Clinical Research Studies | 2021-2025 | 27 | GB 2 | 99.75 |
| Pneumonia and Respiratory Infections | 2021-2025 | 4 | GB 1 | 99.76 |
| Bacterial Infections and Vaccines | 2021-2025 | 2 | GB 1 | 99.43 |
| COVID-19 and Mental Health | 2021-2025 | 16 | GB 5 | 99.64 |
| Respiratory viral infections research | 2021-2025 | 8 | GB 2 | 99.70 |
| COVID-19 Impact on Reproduction | 2021-2025 | 10 | GB 3 | 98.98 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 76 | GB 8 | 99.56 |
| Kawasaki Disease and Coronary Complications | 2021-2025 | 9 | GB 1 | 98.79 |
| SARS-CoV-2 detection and testing | 2021-2025 | 40 | GB 3 | 98.55 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 43 | GB 5 | 96.72 |
| COVID-19 and healthcare impacts | 2021-2025 | 184 | GB 43 | 96.23 |
| Virology and Viral Diseases | 2021-2025 | 41 | GB 4 | 94.21 |
| COVID-19 epidemiological studies | 2021-2025 | 294 | GB 40 | 96.10 |
| Poxvirus research and outbreaks | 2021-2025 | 58 | GB 3 | 94.65 |
| Bacillus and Francisella bacterial research | 2021-2025 | 91 | GB 6 | 91.71 |
| Herpesvirus Infections and Treatments | 2021-2025 | 245 | GB 15 | 90.20 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 620 | GB 55 | 91.30 |
| Respiratory Support and Mechanisms | 2021-2025 | 807 | GB 59 | 92.14 |
| Emergency and Acute Care Studies | 2021-2025 | 956 | GB 87 | 85.18 |
| Streptococcal Infections and Treatments | 2021-2025 | 522 | GB 21 | 82.21 |
| Viral Infections and Outbreaks Research | 2021-2025 | 751 | GB 80 | 80.75 |
| Pregnancy and Medication Impact | 2021-2025 | 606 | GB 53 | 79.29 |
| Infection Control and Ventilation | 2021-2025 | 979 | GB 81 | 72.90 |
| Thermal Regulation in Medicine | 2021-2025 | 455 | GB 34 | 69.00 |
| Parvovirus B19 Infection Studies | 2021-2025 | 493 | GB 15 | 66.67 |
| Dermatological and COVID-19 studies | 2021-2025 | 774 | GB 21 | 49.96 |
